<DOC>
	<DOCNO>NCT02575261</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness CAR-T cell immunotherapy treat EphA2 positive malignant glioma patient .</brief_summary>
	<brief_title>CAR-T Cell Immunotherapy EphA2 Positive Malignant Glioma Patients</brief_title>
	<detailed_description>Chimeric antigen receptor ( CAR ) recombinant receptor antigen-binding T cell activate function . Chimeric antigen receptor T cell Immunotherapy advantage compare conventional immunotherapy , especially deal patient hematologic malignancy solid malignant tumors.This study design novel specific Chimeric antigen receptor aim EphA2 antigen.After CAR-T cell infusion , At periodic interval , investigator evaluate clinical symptom Improved condition disease.Through study , investigator evaluate safty effectiveness CAR-T cell immunotherapy treat EphA2 positive malignant glioma patient .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<criteria>1. primary EphA2 positive patient , best malignant glioma patient . 2. recurrent EphA2 positive patient , best malignant glioma patient . 3 . Patients must evidence adequate bone marrow reserve , hepatic renal function evidence follow laboratory parameter : Absolute neutrophil count great 1500/mm3 . Platelet count great 100,000/mm3 . Hemoglobin great 10g/dl ( patient may receive transfusion meet parameter ) . Total bilirubin &lt; 1.5 time upper limit normal . Serum creatinine less equal 1.6 mg/ml creatinine clearance must great 70 ml/min/1.73m ( 2 ) . Seronegative HIV antibody . Seronegative active hepatitis B , seronegative hepatitis C antibody . Patients must willing practice birth control four month follow treatment.NOTE : woman childbearing age must evidence negative pregnancy test . Patients must willing sign inform consent . 1. patient multiple kind cancars exclude . 2 . Patients uncontrolled hypertension ( &gt; 160/95 ) , unstable coronary disease evidence uncontrolled arrhythmia , unstable angina , decompensated congestive heart failure ( &gt; New York Heart Association Class II ) , myocardial infarction within 6 month study exclude . 3 . Patients follo wing pulmonary function abnormality exclude : FEV ( forced expiratory volume ) , &lt; 30 % predict ; DLCO ( diffuse capacity lung carbon monoxide ) &lt; 30 % predict ( postbronchodilator ) ; Oxygen Saturation less 90 % room air . 4 . Patients severe liver kidney dysfunction consciousness disorder exclude . 5 . Pregnant and/or lactate woman exclude . 6 . Patients active infection , include HIV , exclude , due unknown effect vaccine lymphoid precursor . 7 . Patients type primary immunodeficiency exclude study . 8 . Patients require corticosteroid ( inhale ) exclude . 9 . Patients history T cell tumor exclude . 10 . Patients participate participated clinical trial late 30 day exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>CAR-T cell immunotherapy</keyword>
	<keyword>EphA2</keyword>
	<keyword>malignant glioma</keyword>
</DOC>